Vendor, South San Francisco, CA
Marwell Bio Inc.
UEI PTX1ZT26L8V3, CAGE 967L9
1 award and -$55,000 obligated between August 31, 2026 and August 31, 2026, 100% under full and open competition, against 55.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | -$55,000 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91025C00040Definitive Contract, August 31, 2026, Full and Open Competition After Exclusion of Sources, 55 offers | NIH NCINational Institutes of Health | Eo 14398 Next Generation Dual Targeting Adcs for SCLC Empowered by Generative Ai.NAICS 541715, PSC AN12 | -$55,000 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 1 across 1 awards